Institute for Transfusion Medicine
Graft-versus-Infection effect, Immunomodulation, Antigen-specific T cells, adoptive T-cell transfer
Our research is focusing on the human major histocompatibility complex (MHC) molecules, the induction and modulation of adaptive as well as innate T-cell immune responses and the influence of immunoregulatory cells (e.g. dendritic cells) and biomolecules (e.g. chaperokines). This includes structural characterization of MHC genes through direct sequencing, functional studies to determine peptide binding motifs from recombinant MHC molecules, as well as the identification and expansion of HLA/ligand-specific anti-tumor as well as antiviral T cells. Furthermore we are developing personalized antiviral as well as anti-tumor T-cell immunotherapeutics and established the allogeneic cell registry alloCELL (www.allocell.org), which provides a source of third party T-cell donors. Manufacturing license according to the German Medicines Act (AMG) for isolation of clinical-grade antiviral T cells for the adoptive T-cell transfer by using the interferon-gamma (IFN-) Cytokine Capture Systems (CCS) and overlapping viral peptide pools was obtained.